Objective To investigate the eurative effect and safety of oxaliplatin plus capecitabine with subsequent capecitabine maintenance chemotherapy for patients with advanced gastric cancer. Methods A total of 32 patients were enrolled into this study, they received first line oxaliplatin plus capecitabine (XELOX) chemotherapy. Patients without tumor progression were assigned to the group with capecitabine maintenance chemotherapy. Results: The response rate (RR) of first-line chemotherapy was 46.9% (15/32); 26 patients entered the capecitabine maintenance chemotherapy group, RR was 26.9% (7/26). The median PFS of whole group was 8.9 months, 1 and 2 year survival rate were 56.2% (18/32) and 31.2% (10/32), respectively. The main adverse reactions were nausea, vomiting, diarrhea, bone marrow suppression, neurotoxicity and hand foot syndrome, which can be tolerated. Conclusion XELOX regimen chemotherapy followed by capecitabine maintenance therapy for advanced gastric cancer patients is effective and safe, while bring a certain degree of survival benefit.